Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KRAS
Biotech
Pfizer trims obesity pipeline, axes phase 2 lung disease asset
Pfizer has axed a pulmonary arterial hypertension program, dealing a setback to a long-running effort to treat the lung disease by targeting BMP9.
Nick Paul Taylor
Nov 3, 2026 8:02am
From RAS rivalry to leaked readouts, ESMO brought the data drama
Oct 27, 2026 8:00am
ESMO: Incyte claims ‘neck and neck’ KRAS G12D race with RevMed
Oct 26, 2026 9:45am
ESMO: Roche touts ‘convincing’ KRAS data after phase 3 win
Oct 25, 2026 11:30am
Verastem CEO says RAS drug 'set new benchmark' for tricky cancer
Oct 14, 2026 10:27am
Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D
Sep 28, 2026 7:59am